drugset / Trial / NCT01276600

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

NCT01276600

Phase 1 Completed 32 enrolled HIV Prevention Trials Network
RandomizedParallel-groupOpen-labelHealth-services research

Summary

Describe the dose-proportionality and intra-individual variability of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) at steady-state in healthy human participants taking Truvada® (FTC 200mg/TDF 300 mg) under direct observation.

Timeline

Start
2011-01
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Small molecule 300 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral